myNEO Therapeutics

What myNEO Therapeutics does

myNEO Therapeutics is a Belgian immunogenomics company founded in 2018 and headquartered in Ghent that develops AI-driven technologies to discover tumor antigens for cancer vaccines, T-cell therapies, and biologics. The company's core offering is the ImmunoEngine platform, which combines whole-genomic analysis with proprietary machine learning algorithms — neoMS (attention-based deep learning for MHC-I epitope presentation prediction) and neoIM (random forest-based immunogenicity prediction) — to identify neoantigens and a novel target class called camyotopes derived from the dark genome. Built around this core, the company offers a modular suite of ten specialized tools (myNEO, myCONSTRUCT, mySHARED, myRNA, mySURFACE, myADA, mySELF, myEPITOPE, myPATHOGEN, myINSIGHTS) addressing personalized and off-the-shelf neoantigen discovery, construct design, codon optimization, surface antigen identification, anti-drug antibody risk prediction, and large-scale data analysis.

The company operates a B2B platform-and-services model targeting biologics developers, vaccine developers, and strategic pharma partners. Revenue is generated through technology platform licensing and services (subscription/recurring) as well as partnered development programs (licensing/royalties with milestone payments), supplemented by a proprietary asset library available for partnering. Customers include CureVac (BioNTech) for off-the-shelf mRNA cancer vaccines in NSCLC and undisclosed solid tumors, the University of Liverpool for personalized DNA cancer vaccines in NSCLC, and undisclosed EU and US pharmaceutical partners. The company has achieved three IND/CTA filings in 2025, holds ISO and regulatory approval for clinical use of its technology, and is advancing an internal pipeline including MNE-C261 (MSS-CRC, targeting H1 2027 clinical initiation), MNE-CXX2 (TNBC), MNE-CXX3 (pancreatic cancer), and MNE-P201 (personalized solid tumors). Pricing is quote-based with no publicly disclosed tiers, and engagement occurs through direct enterprise sales.

Name

myNEO Therapeutics

Legal name

myNEO BV

Website

https://myneotx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

myNEO Therapeutics is a Belgian immunogenomics company that applies AI-driven neoantigen discovery and its ImmunoEngine platform to support personalized cancer vaccine, T-cell therapy, and biologics development for pharmaceutical and biotech partners.

Ownership category

akta.pro rank

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Neoantigen discovery platform
• Cancer vaccine antigens
• Immunogenicity prediction software
• Biologics target discovery
• T-cell therapy antigens

Headquarters

HQ city

Ghent

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Platform Licensing & Services: myNEO provides AI-driven technologies as a service to biologics developers, vaccine developers, and pharma partners. The company offers modular solutions that can be used independently or combined into an integrated end-to-end workflow. Services include target discovery, prioritization, optimization, and large-scale data analysis across therapeutic modalities.
2. Partnered Development Programs: myNEO engages in co-development partnerships with pharmaceutical companies (CureVac/BioNTech, University of Liverpool) for both off-the-shelf and personalized therapeutics. These partnerships likely involve milestone payments and potential royalties based on development and commercialization success.
3. Proprietary Asset Licensing: myNEO maintains an asset library of MHC-bound and surface antigen targets in multiple cancer indications available for partnering and licensing to developers of biologics, vaccines, and T-cell therapeutics.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

myNEO Therapeutics provides an AI-driven computational platform called ImmunoEngine that combines whole-genomic and immunologic expertise with proprietary machine learning algorithms (neoMS, neoIM) to discover and validate tumor antigens — neoantigens and the proprietary 'camyotope' dark-genome target class — for use in personalized cancer vaccines, off-the-shelf cancer vaccines, T-cell therapies, and biologics. The offering is delivered as modular tools (myNEO, myCONSTRUCT, mySHARED, myRNA, mySURFACE, myADA, mySELF, myEPITOPE, myPATHOGEN, myINSIGHTS) usable independently or as an integrated end-to-end workflow, plus a proprietary asset library available for licensing and internal camyotope-based pipeline programs.

Product overview

myNEO Therapeutics operates a modular platform-plus-modules architecture built around the ImmunoEngine core platform. ImmunoEngine combines deep whole-genomic and immunologic expertise with AI-driven technologies for antigen prediction and target prioritization in immune-based therapies. The platform includes multiple specialized modules: myNEO (personalized neoantigen discovery), myCONSTRUCT (construct design), mySHARED (shared antigen discovery), myRNA (codon optimization), mySURFACE (surfaceome target discovery), myADA (ADA risk prediction), mySELF (autoimmune target discovery), myEPITOPE (immunogenicity screening), myPATHOGEN (infectious disease targets), and myINSIGHTS (large-scale data analysis). These are powered by proprietary algorithms neoMS (MHC presentation prediction) and neoIM (immunogenicity prediction). The company also develops internal camyotope-based programs (MNE-C261, MNE-CXX2, MNE-CXX3, MNE-P201) and maintains partnered programs with CureVac/BioNTech and academic institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• ImmunoEngine platform Core computational platform combining whole-genomic and immunologic expertise with AI-driven technologies for target discovery and prioritization in immune-based therapies; supports end-to-end workflow across cancer vaccines, biologics, and T-cell therapies.
• myNEO (personalized neoantigen discovery) AI-powered, IVD-ready personalized neoantigen discovery service for onco immunotherapeutic modalities, delivering results from whole-genome sequencing to neoantigen selection in five business days.
• myCONSTRUCT (construct design) Computational construct design solution that reduces unwanted junctional epitopes, minimizes unintended immunodominance, and preserves therapeutic focus for multi-epitope therapeutics.
• mySHARED (shared MHC-bound target discovery) AI-powered discovery of shared MHC-bound targets for off-the-shelf immunotherapeutic modalities, performing large cohort analyses for shared target discovery in specific cancer patient populations.
• myRNA (codon optimization) Advanced codon optimization engine integrating structural stability and codon usage with comprehensive constraint-aware design for multi-epitope RNA therapeutics.
• mySURFACE (surfaceome target discovery) AI-powered identification of surface antigens for biological therapeutic modalities, performing large-scale patient cohort analyses for biologics developers.
• myADA (anti-drug antibody risk prediction) Next-generation Anti-Drug Antibody risk prediction tool using MHC class II epitope immunogenicity modeling to identify CD4+ T-cell epitopes capable of initiating ADA responses for proactive biologic immunogenicity control.
• mySELF (autoimmune target discovery) AI-powered discovery of immunogenic and tolerogenic self-antigens for autoimmune disease research, enabling rational prioritization of pathogenic candidates and tolerance-oriented strategies.
• myEPITOPE (immunogenicity screening) High-precision immunogenicity prediction tool for CD8+ T-cell responses using the proprietary neoIM algorithm, enabling de-risked preclinical validation.
• myPATHOGEN (infectious disease target discovery) AI-powered discovery of pathogen-derived targets for infectious disease therapeutic modalities, identifying highly conserved and immunogenic epitopes across pathogen strains.
• myINSIGHTS (large-scale immuno-genomic data analysis) Large-scale immuno-genomic dataset analysis supporting biomarker identification, response prediction, trial design optimization, and data imputation for data-driven decision-making.
• neoMS algorithm Best-in-class HLA-agnostic MHC-I epitope presentation prediction algorithm using attention-based deep learning trained on 386,647 epitopes; achieves positive predictive value of 0.61 at 40% recall on patient-derived data.
• neoIM algorithm First-in-class immunogenicity prediction algorithm that predicts activation of CD4+ and CD8+ T-cells by a given epitope using a random forest classifier trained on MHC-presented non-self peptides.
• neoHUB data platform Web-based platform for navigating complex tumor and immune sequencing data, providing a comprehensive overview of the full patient dataset for clinicians and clinical researchers.
• Camyotopes asset library Proprietary library of dark-genome-derived tumor antigens representing a novel target class for next-generation immunotherapies, characterized as cancer-exclusive with high abundance, validated expression, translation, MHC-I presentation, and immunogenicity; available for partnering and licensing.
• MNE-C261 (MSS-CRC off-the-shelf mRNA-LNP camyotope vaccine) Internal off-the-shelf mRNA-LNP vaccine candidate targeting 26 CRC-specific camyotope antigens for microsatellite-stable colorectal cancer, with clinical phase initiation targeted for H1 2027.
• MNE-CXX2 (TNBC off-the-shelf mRNA camyotope vaccine) Internal off-the-shelf mRNA camyotope vaccine in development for triple-negative breast cancer.
• MNE-CXX3 (pancreatic cancer off-the-shelf mRNA camyotope vaccine) Internal off-the-shelf mRNA camyotope vaccine in development for pancreatic cancer.
• MNE-P201 (personalized mRNA neoantigen vaccine) Internal personalized mRNA neoantigen vaccine in development for solid tumors.

Quantifiable outcome

• neoMS achieves positive predictive value of 0.61 at 40% recall on patient-derived test dataset
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Partnerships

Four partnerships are on record, tiered core and major.

• CureVac (BioNTech)coreStrategic or Co-development PartnerCureVac (BioNTech) partnership for off-the-shelf mRNA cancer vaccines targeting NSCLC and an undisclosed solid tumor indication. One program has received IND/CTA approval with recruitment underway. This represents a core strategic partnership for advancing myNEO's technology in mRNA vaccine development.
• University of LiverpoolcoreStrategic or Co-development PartnerPartnership with University of Liverpool for development of personalized DNA cancer vaccines targeting NSCLC. The collaboration leverages myNEO's ImmunoEngine platform for neoantigen discovery combined with the university's clinical research capabilities.
• Undisclosed EU PartnermajorStrategic or Co-development PartnerUndisclosed European pharmaceutical partner for development of personalized DNA cancer vaccines targeting solid tumors.
• Undisclosed US PartnermajorStrategic or Co-development PartnerUndisclosed US-based pharmaceutical partner for development of personalized MVA cancer vaccines targeting solid tumors.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Lantern Pharma: Lantern Pharma applies AI and machine learning to oncology drug development, with a focus on targeted therapeutics. Comparable to myNEO in leveraging AI for cancer therapy development, though Lantern focuses on small molecule rather than biologics/vaccines.

Direct peers

• Personalis: Personalis provides AI-driven genomic and immune profiling services for cancer therapy development, including neoantigen identification through its NeXT Personal platform. Comparable to myNEO as an analytical technology partner serving pharma oncology programs.
• BioNTech: BioNTech develops mRNA-based cancer immunotherapies including individualized neoantigen vaccines (e.g., BNT122/Autogene cevumeran) and acquired Neon Therapeutics to deepen its neoantigen capabilities. As myNEO's anchor partner through CureVac, BioNTech represents the most directly comparable competitor-customer dynamic in personalized cancer vaccines.
• Gritstone bio: Gritstone bio develops neoantigen-based immunotherapies including personalized cancer vaccines (GRANITE) and off-the-shelf vaccine approaches (SLATE). Directly comparable to myNEO in neoantigen discovery and cancer vaccine development, with similar focus on solid tumor indications.
• Evaxion Biotech: Evaxion Biotech develops AI-powered immunology platforms for neoantigen-based cancer vaccines and infectious disease vaccines. Highly comparable to myNEO in applying AI to identify and prioritize neoantigens for personalized cancer immunotherapy.
• CureVac: CureVac is an mRNA therapeutics company developing cancer vaccines and other mRNA-based therapies, and is myNEO's named partner (now part of BioNTech). Comparable as an mRNA cancer vaccine developer leveraging myNEO's neoantigen discovery technology.
• Neon Therapeutics (acquired by BioNTech): Neon Therapeutics was a pioneer in personalized neoantigen cancer vaccines (NEO-PV-01) before being acquired by BioNTech. Closely comparable to myNEO's mission and platform approach in the neoantigen vaccine space, and effectively sets the consolidation playbook myNEO could face.

Broad incumbents

• Genentech (Roche): Genentech/Roche is a major biologics developer with extensive oncology and immunology capabilities, including surface antigen and antibody-based therapeutics. Comparable to myNEO as a potential customer/partner for the mySURFACE and myADA platform modules serving biologics developers.
• Tempus AI: Tempus AI provides a broad AI-driven precision medicine platform spanning molecular profiling, data analytics, and therapeutic development support. Comparable to myNEO's myINSIGHTS offering in large-scale immuno-genomic data analysis for biomarker and trial design support.
• Moderna: Moderna operates a broad mRNA therapeutics platform with oncology programs including personalized cancer vaccines (mRNA-4157/V940 with Merck). Comparable to myNEO in the mRNA cancer vaccine modality, but with substantially greater scale and a much broader pipeline across infectious disease and other therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/myneotx

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about myNEO Therapeutics